Cargando…

Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease

Biological intervention for Crohn's Disease (CDs) patients, mainly using anti-TNF antibodies, is often an efficient therapeutic solution. Nonetheless, data defining the administration timing to maximize the chances of clinical remission are lacking. The objective of this “real-life” retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mastronardi, Mauro, Curlo, Margherita, Cavalcanti, Elisabetta, Burattini, Osvaldo, Cuppone, Renato, Tauro, Romina, De Santis, Stefania, Serino, Grazia, Pesole, Pasqua Letizia, Stasi, Elisa, Caruso, Maria Lucia, Donghia, Rossella, Guerra, Vito, Giorgio, Pietro, Chieppa, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838026/ https://www.ncbi.nlm.nih.gov/pubmed/31737635 http://dx.doi.org/10.3389/fmed.2019.00234

Ejemplares similares

Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study
por: Liso, Marina, et al.
Publicado: (2022)

90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients
por: Pesole, Pasqua Letizia, et al.
Publicado: (2023)

Contribution of macro- and micronutrients intake to gastrointestinal cancer mortality in the ONCONUT cohort: Classical vs. modern approaches
por: Donghia, Rossella, et al.
Publicado: (2023)

Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease
por: Labarile, Nunzia, et al.
Publicado: (2022)

Nutritional Keys for Intestinal Barrier Modulation
por: De Santis, Stefania, et al.
Publicado: (2015)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Secretory leukoprotease inhibitor is required for efficient quercetin-mediated suppression of TNFα secretion
por: De Santis, Stefania, et al.
Publicado: (2016)

Altered miRNAs Expression Correlates With Gastroenteropancreatic Neuroendocrine Tumors Grades
por: Cavalcanti, Elisabetta, et al.
Publicado: (2020)

miR-369-3p modulates inducible nitric oxide synthase and is involved in regulation of chronic inflammatory response
por: Scalavino, Viviana, et al.
Publicado: (2020)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Food Network Analysis in Non-Obese Patients with or without Steatosis
por: Donghia, Rossella, et al.
Publicado: (2023)

Pyoderma gangrenosum in ulcerative colitis patient treated with vedolizumab: adsorptive granulocyte/monocyte apheresis as a new therapeutic option refractory cases – a case report and literature review
por: Mastronardi, Mauro, et al.
Publicado: (2023)

Serum Cytokine and miRNA Levels Are Differently Expressed in Right- and Left-Sided Colon Cancer
por: De Nunzio, Valentina, et al.
Publicado: (2023)

Iatrogenic Kaposi sarcoma of the terminal ileum following short-term treatment with immunomodulators for Crohn disease: A case report
por: Stasi, Elisa, et al.
Publicado: (2019)

The Replacement of Only One Portion of Starchy Carbohydrates with Green Leafy Vegetables Regresses Mid and Advanced Stages of NAFLD: Results from a Prospective Pilot Study
por: De Nucci, Sara, et al.
Publicado: (2023)

Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma
por: Cagnin, Silvia, et al.
Publicado: (2023)

Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy
por: Lampignano, Luisa, et al.
Publicado: (2021)

Early administration of adalimumab for paediatric uveitis due to Behçet’s disease
por: Hiyama, Tomona, et al.
Publicado: (2019)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: Panahi, M., et al.
Publicado: (2021)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

Polyphenol Enriched Diet Administration During Pregnancy and Lactation Prevents Dysbiosis in Ulcerative Colitis Predisposed Littermates
por: De Santis, Stefania, et al.
Publicado: (2021)

Quercetin Administration Suppresses the Cytokine Storm in Myeloid and Plasmacytoid Dendritic Cells
por: Verna, Giulio, et al.
Publicado: (2021)

Age-Related Dietary Habits and Blood Biochemical Parameters in Patients with and without Steatosis—MICOL Cohort
por: Donghia, Rossella, et al.
Publicado: (2023)

Administration of adalimumab in paediatric patients with juvenile idiopathic arthritis in South Ural region
por: Glazyrina, Galina
Publicado: (2014)

A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease
por: Fu, Yin-mei, et al.
Publicado: (2017)

Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
por: Zeisler, Bella, et al.
Publicado: (2015)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
por: Xu, Lankai Cathy, et al.
Publicado: (2023)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
por: Minden, Kirsten, et al.
Publicado: (2014)

A Case of New-Onset Vitiligo in a Healthy Volunteer After Administration of Adalimumab
por: Yang, Hee Joo, et al.
Publicado: (2021)

Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
por: Abdelqader, Abdelhai, et al.
Publicado: (2016)

Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
por: Atsawarungruangkit, Amporn, et al.
Publicado: (2017)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Development of Disseminated Tuberculosis with Intestinal Involvement due to Adalimumab Administration Despite Latent Tuberculosis Treatment
por: Ikuta, Kozo, et al.
Publicado: (2019)

Remote Monitoring Empowerment of Patients with IBDs during the SARS-CoV-2 Pandemic
por: Mastronardi, Mauro, et al.
Publicado: (2020)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Reversible proteinuria after adalimumab discontinuation in a patient with Crohn's disease
por: Katsanos, Konstantinos H., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jhj7s0nosrutg6irh0nvoplq6j